Samsung Bioepis Enters into a Strategic Partnership with NIPRO for Commercialization of Multiple Biosimilars in Japan

Samsung Bioepis (President and CEO: Kyung-Ah Kim) has entered into a license, development and commercialization agreement with NIPRO Corporation (President: Yoshihiko Sano) for multiple biosimilar candidates in Japan. (image=Samsung Bioepis Co., Ltd)

Samsung Bioepis Co., Ltd. (“Samsung Bioepis”) announced today that the company has entered into a license, development and commercialization agreement with NIPRO Corporation (“NIPRO”) for multiple biosimilar candidates including SB17, ustekinumab biosimilar candidate, in Japan.

Under the terms of the agreement, Samsung Bioepis will be responsible for the development, manufacture and supply of the medicines, while NIPRO will be responsible for commercialization of the medicines in Japan.

“This partnership marks an important step towards expanding our footprint in Japan. Biosimilars have a great potential to bring cost savings and widen access to treatments for healthcare systems, providers, and patients in Japan.

We look forward to collaborating with NIPRO, a company renowned for its high-quality medical devices and healthcare solutions, to accelerate access to treatments in the Japanese market,” said Kyung-Ah Kim, President and Chief Executive Officer of Samsung Bioepis. “We will continue to advance our development platform and innovate access to treatments for healthcare systems, payers, physicians, and patients around the world.”